Challenges and future perspectives of T cell immunotherapy in cancer

Immunology Letters

Volumn 166, Issue 2, 2015, Pages 117-133

  de Aquino, Maria Teresa P ^a   Malhotra, Anshu ^a,d   Mishra, Manoj K ^b   Shanker, Anil ^a,c  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b ALABAMA STATE UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; Checkpoint inhibition; Immune activation; Immunoediting; Immunosuppression; T lymphocyte; Tumour escape

Indexed keywords

BEVACIZUMAB; CD3 ANTIGEN; DURVALUMAB; GANGLIOSIDE; INTERLEUKIN 1; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA1; IMMUNOLOGIC FACTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANTIGEN RECOGNITION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CARCINOGENESIS; COMPLEX FORMATION; CYTOKINE PRODUCTION; DRUG EFFICACY; GENETIC ENGINEERING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SMALL CELL LUNG CANCER; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UROGENITAL TRACT CANCER; ANIMAL; BIOLOGICAL THERAPY; BYSTANDER EFFECT; CELL COMMUNICATION; CELL TRANSFORMATION; GENE THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; BYSTANDER EFFECT; CELL COMMUNICATION; CELL TRANSFORMATION, NEOPLASTIC; CELL- AND TISSUE-BASED THERAPY; GENETIC ENGINEERING; GENETIC THERAPY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84932599824     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.05.018     Document Type: Review

References (295)

1. Coulie P.G., Hanagiri T., Takenoyama M. From tumor antigens to immunotherapy. Int. J. Clin. Oncol. 2001, 6:163-170.
2. Van Der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E.S., et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 2002, 188:51-64.
3. Coggin J.H., Barsoum A.L., Rohrer J.W., Thurnher M., Zeis M. Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. Anticancer Res. 2005, 25:2345-2355.
4. Kazemi T., Younesi V., Jadidi-Niaragh F., Yousefi M. Immunotherapeutic approaches for cancer therapy: an updated review. Artif. Cells Nanomed. Biotechnol. 2015, 1-11. (Epub ahead of print).
5. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 2003, 3:666-675.
6. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 2003, 198:569-580.
7. Ryschich E., Notzel T., Hinz U., Autschbach F., Ferguson J., Simon I., et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin. Cancer Res. 2005, 11:498-504.
8. Gottschalk S., Heslop H.E., Rooney C.M. Adoptive immunotherapy for EBV-associated malignancies. Leuk. Lymphoma 2005, 46:1-10.
9. Hanson H.L., Donermeyer D.L., Ikeda H., White J.M., Shankaran V., Old L.J., et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000, 13:265-276.
10. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 2002, 195:423-435.
11. Cordaro T.A., de Visser K.E., Tirion F.H., Schumacher T.N., Kruisbeek A.M. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?. J. Immunol. 2002, 168:651-660.
12. Morgan D.J., Kreuwel H.T., Fleck S., Levitsky H.I., Pardoll D.M., Sherman L.A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 1998, 160:643-651.
13. Shanker A., Schmitt-Verhulst A.M., Inderberg-Suso E.M. Monoclonal CD8 T lymphocytes recognizing a self tumor associated antigen provide resistance to tumor development in vivo in synergy with NK cells. FASEB J. 2004, 18:A83-A90.
14. Gillmore R., Xue S., Holler A., Kaeda J., Hadjiminas D., Healy V., et al. Detection of Wilm's tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin. Cancer Res. 2006, 12:34-42.
15. Touloukian C.E., Leitner W.W., Robbins P.F., Li Y.F., Kang X., Lapointe R., et al. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res. 2002, 62:5144-5147.
16. Touloukian C.E., Leitner W.W., Schnur R.E., Robbins P.F., Li Y., Southwood S., et al. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J. Immunol. 2003, 170:1579-1585.
17. Hong J.J., Rosenberg S.A., Dudley M.E., Yang J.C., White D.E., Butman J.A., et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin. Cancer Res. 2010, 16:4892-4898.
18. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365:1673-1683.
19. Griffioen M., Borghi M., Schrier P.I., Osanto S., Schadendorf D. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunol. Immunother. 2004, 53:715-722.
20. Yamanaka R., Honma J., Tsuchiya N., Yajima N., Kobayashi T., Tanaka R. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma. J. Neurooncol. 2005, 72:107-113.
21. Liau L.M., Prins R.M., Kiertscher S.M., Odesa S.K., Kremen T.J., Giovannone A.J., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 2005, 11:5515-5525.
22. Yu J.S., Liu G.T., Ying H., Yong W.H., Black K.L., Wheeler C.J. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004, 64:4973-4979.
23. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 1997, 186:645-653.
24. Rosenberg S.A., Yang J.C., Robbins P.F., Wunderlich J.R., Hwu P., Sherry R.M., et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J. Immunother. 2003, 26:385-393.
25. Cordaro T.A., de Visser K.E., Tirion F.H., Graus Y.M., Haanen J.B., Kioussis D., et al. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Eur. J. Immunol. 2000, 30:1297-1307.
26. Stewart B.H., Hoskin D.W. Regulatory role of CD8 in major histocompatibility complex-unrestricted tumoricidal activity of mouse T cells activated with anti-CD3 monoclonal antibody. Immunol. Invest. 1997, 26:601-614.
27. Kessler B., Hudrisier D., Cerottini J.C., Luescher I.F. Role of CD8 in aberrant function of cytotoxic T lymphocytes. J. Exp. Med. 1997, 186:2033-2038.
28. Whiteside T.L. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer?. Cancer Immunol. Immunother. 2004, 53:865-878.
29. Mozaffari F., Hansson L., Kiaii S., Ju X.L., Rossmann E.D., Rabbani H., et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br. J. Haematol. 2004, 124:315-324.
30. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992, 258:1795-1798.
31. Matsuda M., Petersson M., Lenkei R., Taupin J.L., Magnusson I., Mellstedt H., et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 1995, 61:765-772.
32. Ohno H., Aoe T., Taki S., Kitamura D., Ishida Y., Rajewsky K., et al. Developmental and functional impairment of T cells in mice lacking CD3 zeta chains. EMBO J. 1993, 12:4357-4366.
33. Finke J.H., Zea A.H., Stanley J., Longo D.L., Mizoguchi H., Tubbs R.R., et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993, 53:5613-5616.
34. Nakagomi H., Petersson M., Magnusson I., Juhlin C., Matsuda M., Mellstedt H., et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993, 53:5610-5612.
35. Gunji Y., Hori S., Aoe T., Asano T., Ochiai T., Isono K., et al. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn. J. Cancer Res. 1994, 85:1189-1192.
36. Maccalli C., Pisarra P., Vegetti C., Sensi M., Parmiani G., Anichini A. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J. Immunol. 1999, 163:6912-6923.
37. Dworacki G., Meidenbauer N., Kuss I., Hoffmann T.K., Gooding W., Lotze M., et al. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin. Cancer Res. 2001, 7:947s-957s.
38. Maki A., Matsuda M., Asakawa M., Kono H., Fujii H., Matsumoto Y. Decreased expression of CD28 coincides with the down-modulation of CD3 zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J. Gastroenterol. Hepatol. 2004, 19:1348-1356.
39. Maki A., Matsuda M., Asakawa M., Kono H., Fujii H., Matsumoto Y. Decreased CD3 zeta molecules of T lymphocytes from patients with hepatocellular carcinoma associated with hepatitis C virus. Hepatol. Res. 2003, 27:272-278.
40. Franco J.L., Ghosh P., Wiltrout R.H., Carter C.R., Zea A.H., Momozaki N., et al. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res. 1995, 55:3840-3846.
41. Ghosh P., Sica A., Young H.A., Ye J., Franco J.L., Wiltrout R.H., et al. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res. 1994, 54:2969-2972.
42. Li X., Liu J., Park J.K., Hamilton T.A., Rayman P., Klein E., et al. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res. 1994, 54:5424-5429.
43. Zea A.H., Ochoa M.T., Ghosh P., Longo D.L., Alvord W.G., Valderrama L., et al. Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect. Immun. 1998, 66:499-504.
44. Hirst W., Buggins A., Mufti G. Central role of leukemia-derived factors in the development of leukemia-associated immune dysfunction. Hematol. J. 2001, 2:2-17.
45. Buggins A.G., Milojkovic D., Arno M.J., Lea N.C., Mufti G.J., Thomas N.S., et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J. Immunol. 2001, 167:6021-6030.
46. Healy C.G., Simons J.W., Carducci M.A., DeWeese T.L., Bartkowski M., Tong K.P., et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998, 32:109-119.
47. Bronstein-Sitton N., Cohen-Daniel L., Vaknin I., Ezernitchi A.V., Leshem B., Halabi A., et al. Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat. Immunol. 2003, 4:957-964.
48. Soudja S.M., Wehbe M., Mas A., Chasson L., de Tenbossche C.P., Huijbers I., et al. Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. Cancer Res. 2010, 70:3515-3525.
49. Grange M., Buferne M., Verdeil G., Leserman L., Schmitt-Verhulst A.M., Auphan-Anezin N. Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma. Cancer Res. 2012, 72:76-87.
50. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
51. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 1999, 189:1363-1372.
52. Fallarino F., Vacca C., Orabona C., Belladonna M.L., Bianchi R., Marshall B., et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int. Immunol. 2002, 14:65-68.
53. Mellor A.L., Keskin D.B., Johnson T., Chandler P., Munn D.H. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol. 2002, 168:3771-3776.
54. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297:1867-1870.
55. Mellor A.L., Baban B., Chandler P., Marshall B., Jhaver K., Hansen A., et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003, 171:1652-1655.
56. Munn D.H., Sharma M.D., Mellor A.L. Ligation of B7-1/B7-2 by human CD4(+) T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 2004, 172:4100-4110.
57. Sedlmayr P., Semlitsch M., Gebru G., Karpf E., Reich O., Tang T., et al. Expression of indoleamine 2,3-dioxygenase in carcinoma of human endometrium and uterine cervix. Developments in Tryptophan and Serotonin Metabolism 2003, 91-95.
58. Matlack R., Yeh K., Rosini L., Gonzalez D., Taylor J., Silberman D., et al. Peritoneal macrophages suppress T-cell activation by amino acid catabolism. Immunology 2006, 117:386-395.
59. Silberman D., Bucknum A., Kozlowski M., Matlack R., Riggs J. Cytokine treatment of macrophage suppression of T cell activation. Immunobiology 2010, 215:70-80.
60. Lee G.K., Park H.J., Macleod M., Chandler P., Munn D.H., Mellor A.L. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002, 107:452-460.
61. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A., Extermann M., et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer 2002, 101:151-155.
62. Watkins S.K., Zhu Z., Riboldi E., Shafer-Weaver K.A., Stagliano K.E., Sklavos M.M., et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 2011, 121:1361-1372.
63. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol. Med. 2004, 10:15-18.
64. Godin-Ethier J., Hanafi L.A., Piccirillo C.A., Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin. Cancer Res. 2011, 17:6985-6991.
65. Johnson B.A., Baban B., Mellor A.L. Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 2009, 1:645-661.
66. Schroecksnadel K., Winkler C., Fuith L.C., Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. 2005, 223:323-329.
67. Slaney C.Y., Toker A., La Flamme A., Backstrom B.T., Harper J.L. Naive blood monocytes suppress T-cell function. A possible mechanism for protection from autoimmunity. Immunol. Cell Biol. 2011, 89:7-13.
68. Gelderman K.A., Hultqvist M., Pizzolla A., Zhao M., Nandakumar K.S., Mattsson R., et al. Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species. J. Clin. Invest. 2007, 117:3020-3028.
69. Doedens A.L., Stockmann C., Rubinstein M.P., Liao D., Zhang N., DeNardo D.G., et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010, 70:7465-7475.
70. Hakomori S., Handa K. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett. 2002, 531:88-92.
71. Birkle S., Zeng G., Gao L., Yu R.K., Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003, 85:455-463.
72. Ravindranath M.H., Muthugounder S., Presser N., Ye X., Brosman S., Morton D.L. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int. J. Cancer 2005, 116:368-377.
73. Santin A.D., Ravindranath M.H., Bellone S., Muthugounder S., Palmieri M., O'Brien T.J., et al. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. Br. J. Obstet. Gynaecol. 2004, 111:613-618.
74. De Toni L., Marconi S., Nardelli E., Alberti D., Borsellino G., Fracasso G., et al. Gangliosides act as onconeural antigens in paraneoplastic neuropathies. J. Neuroimmunol. 2004, 156:178-187.
75. Dillman R.O., Cornforth A.N., Nistor G. Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. Expert Opin. Biol. Ther. 2013, 13:643-656.
76. Peguet-Navarro J., Sportouch M., Popa I., Berthier O., Schmitt D., Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 2003, 170:3488-3494.
77. Shen W., Ladisch S. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell. Immunol. 2002, 220:125-133.
78. Thornton M.V., Kudo D., Rayman P., Horton C., Molto L., Cathcart M.K., et al. Degradation of NF-{kappa}B in T cells by gangliosides expressed on renal cell carcinomas. J. Immunol. 2004, 172:3480-3490.
79. Bharti A.C., Singh S.M. Inhibition of macrophage nitric oxide production by gangliosides derived from a spontaneous T cell lymphoma: the involved mechanisms. Nitric Oxide 2003, 8:75-82.
80. Bharti A.C., Singh S.M. Gangliosides derived from a T cell lymphoma inhibit bone marrow cell proliferation and differentiation. Int. Immunopharmacol. 2001, 1:155-165.
81. Bharti A.C., Singh S.M. Induction of apoptosis in bone marrow cells by gangliosides produced by a T cell lymphoma. Immunol. Lett. 2000, 72:39-48.
82. Hamamura K., Furukawa K., Hayashi T., Hattori T., Nakano J., Nakashima H., et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11041-11046.
83. Muthing J., Meisen I., Kniep B., Haier J., Senninger N., Neumann U., et al. Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues are receptors for the anticancer drug rViscumin. FASEB J. 2004, 18:103.
84. Guthmann M.D., Bitton R.J., Carnero A.J.L., Gabri M.R., Cinat G., Koliren L., et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine - a report on safety and immunogenicity. J. Immunother. 2004, 27:442-451.
85. Zou W., Borrelli S., Gilbert M., Liu T.M., Pon R.A., Jennings H.J. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J. Biol. Chem. 2004, 279:25390-25399.
86. Fujimoto Y., Izumoto S., Suzuki T., Kinoshita M., Kagawa N., Wada K., et al. Ganglioside GM3 inhibits proliferation and invasion of glioma. J. Neurooncol. 2005, 71:99-106.
87. Osorio M., Gracia E., Reigosa E., Hernandez J., de la Torre A., Saurez G., et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag. Res. 2012, 4:341-345.
88. Torre-Amione G., Beauchamp R.D., Koeppen H., Park B.H., Schreiber H., Moses H.L., et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1486-1490.
89. Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 2001, 7:1118-1122.
90. Peng Y., Gorelik L., Laouar Y., Li M.O., Flavell R.A. TGFbeta-mediated immunoregulation. Ernst Scher. Res. Found Workshop 2006, 155-160.
91. Grothey A., Heistermann P., Philippou S., Voigtmann R. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br. J. Cancer 1998, 77:801-807.
92. Sanchez-Rovira P., Jimenez E., Carracedo J., Barneto I.C., Ramirez R., Aranda E. Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity. Eur. J. Cancer 1998, 34:394-398.
93. Feng T., Zhou J.H., Liu J., Ye F., Lu W., Xie X. Altered expression levels of HLA class and costimulatory molecules on circulating monocytes from patients with cervical intraepithelial neoplasia and squamous cervical cancer. Mol. Med. Rep. 2012, 6:1301-1304.
94. Tsutsumi S., Kuwano H., Shimura T., Morinaga N., Mochiki E., Asao T. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000, 89:2560-2564.
95. MacLean G.D., Reddish M.A., Longenecker B.M. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J. Immunother. 1997, 20:70-78.
96. Shanker A., Singh S.M., Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution - 2. Induction of apoptosis in thymocytes. Tumor Biol. 2000, 21:315-327.
97. Shanker A., Singh S.M., Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution - 1. Alterations in the CD4/CD8 distribution in thymocytes. Tumor Biol. 2000, 21:288-298.
98. Taylor D.D., Gercel-Taylor I.E., Lyons K.S., Stanson J., Whiteside T.L. T-cell apoptosis and suppression of T-cell receptor/CD3-xi by fas ligand-containing membrane vesicles shed from ovarian tumors. Clin. Cancer Res. 2003, 9:5113-5119.
99. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 1999, 20:46-52.
100. Ohno S., Inagawa H., Dhar D.K., Fujii T., Ueda S., Tachibana M., et al. Role of tumor-associated macrophages (TAM) in advanced gastric carcinoma: the impact on FasL-mediated counterattack. Anticancer Res. 2005, 25:463-470.
101. Martinez-Lorenzo M.J., Anel A., Alava M.A., Pineiro A., Naval J., Lasierra P., et al. The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp. Cell Res. 2004, 295:315-329.
102. Ryan A.E., Shanahan F., O'Connell J., Houston A.M. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 2005, 65:9817-9823.
103. Restifo N.P. Countering the 'counterattack' hypothesis. Nat. Med. 2001, 7:259.
104. Shanker A., Brooks A.D., Jacobsen K.M., Wine J.W., Wiltrout R.H., Yagita H., et al. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res. 2009, 69:6615-6623.
105. Kim R., Emi M., Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin. Exp. Immunol. 2006, 146:189-196.
106. Wang Y., Han G., Wang K., Liu G., Wang R., Xiao H., et al. Tumor-derived GM-CSF promotes inflammatory colon carcinogenesis via stimulating epithelial release of VEGF. Cancer Res. 2014, 74:716-726.
107. Huang Y., Lin L., Shanker A., Malhotra A., Yang L., Dikov M.M., et al. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res. 2011, 71:6122-6131.
108. Visco C., Vassilakopoulos T.P., Kliche K.O., Nadali G., Viviani S., Bonfante V., et al. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk. Lymphoma 2004, 45:2085-2092.
109. Fayad L., Keating M.J., Reuben J.M., O'Brien S., Lee B.N., Lerner S., et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001, 97:256-263.
110. Kim J., Modlin R.L., Moy R.L., Dubinett S.M., McHugh T., Nickoloff B.J., et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J. Immunol. 1995, 155:2240-2247.
111. Pawelec G., Schlotz E., Rehbein A. IFN-alpha regulates IL 10 production by CML cells in vitro. Cancer Immunol. Immunother. 1999, 48:430-434.
112. Richter G., Kruger-Krasagakes S., Hein G., Huls C., Schmitt E., Diamantstein T., et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 1993, 53:4134-4137.
113. Di Carlo E., Coletti A., Modesti A., Giovarelli M., Forni G., Musiani P. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur. Cytokine Netw. 1998, 9:61-68.
114. Yang G., Hellstrom K.E., Mizuno M.T., Chen L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immunol. 1995, 155:3897-3903.
115. Taga K., Chretien J., Cherney B., Diaz L., Brown M., Tosato G. Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J. Clin. Invest. 1994, 94:251-260.
116. Pawelec G., Hambrecht A., Rehbein A., Adibzadeh M. Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal-induced cell death but only anti-fas antibody can prevent activation-induced cell death. Cytokine 1996, 8:877-881.
117. Steinbrink K., Graulich E., Kubsch S., Knop J., Enk A.H. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002, 99:2468-2476.
118. Liu L., Rich B.E., Inobe J., Chen W., Weiner H.L. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int. Immunol. 1998, 10:1017-1026.
119. Carbone E., Terrazzano G., Ruggiero G., Zanzi D., Ottaiano A., Manzo C., et al. Recognition of autologous dendritic cells by human NK cells. Eur. J. Immunol. 1999, 29:4022-4029.
120. Hagenbaugh A., Sharma S., Dubinett S.M., Wei S.H., Aranda R., Cheroutre H., et al. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 1997, 185:2101-2110.
121. Ahn Y.H., Hong S.O., Kim J.H., Noh K.H., Song K.H., Lee Y.H., et al. The siRNA cocktail targeting IL-10 receptor and TGF-beta receptor on dendritic cells potentiates tumor antigen-specific CD8 T cell immunity. Clin. Exp. Immunol. 2015, 181:164-178.
122. Huang S., Ullrich S.E., Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J. Interferon Cytokine Res. 1999, 19:697-703.
123. Chard L.S., Maniati E., Wang P., Zhang Z., Gao D., Wang J., et al. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clin. Cancer Res. 2015, 21:405-416.
124. Frucht D.M., Fukao T., Bogdan C., Schindler H., O'Shea J.J., Koyasu S. IFN-gamma-production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 2001, 22:556-560.
125. Puddu P., Carollo M., Pietraforte I., Spadaro F., Tombesi M., Ramoni C., et al. IL-2 induces expression and secretion of IFN-gamma in murine peritoneal macrophages. J. Leuk. Biol. 2005, 78:686-695.
126. Allavena P., Giardina G., Bianchi G., Mantovani A. IL-15 is chemotactic for natural killer cells and stimulates their adhesion to vascular endothelium. J. Leuk. Biol. 1997, 61:729-735.
127. Bronte V., Wang M., Overwijk W.W., Surman D.R., Pericle F., Rosenberg S.A., et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 1998, 161:5313-5320.
128. Kusmartsev S., Nefedova Y., Yoder D., Gabrilovich D.I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 2004, 172:989-999.
129. Vermi W., Bonecchi R., Facchetti F., Bianchi D., Sozzani S., Festa S., et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 2003, 200:255-268.
130. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
131. Otsuji M., Kimura Y., Aoe T., Okamoto Y., Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13119-13124.
132. Kumar A., Singh S.M., Parajuli P. Modulatory effect of Dalton's lymphoma cells on the production of reactive nitrogen intermediates, interleukin-1 and tumor necrosis factor by murine peritoneal macrophages. Neoplasma 1994, 41:363-369.
133. Parajuli P., Singh S.M. Alteration in IL-1 and arginase activity of tumor-associated macrophages: a role in the promotion of tumor growth. Cancer Lett. 1996, 107:249-256.
134. Aoe T., Okamoto Y., Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med. 1995, 181:1881-1886.
135. Rodriguez P.C., Zea A.H., DeSalvo J., Culotta K.S., Zabaleta J., Quiceno D.G., et al. l-Arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 2003, 171:1232-1239.
136. Rodriguez P.C., Ochoa A.C. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin. Cancer Biol. 2006, 16:66-72.
137. Makino Y., Nakamura H., Ikeda E., Ohnuma K., Yamauchi K., Yabe Y., et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J. Immunol. 2003, 171:6534-6540.
138. Link A.A., Kino T., Worth J.A., McGuire J.L., Crane M.L., Chrousos G.P., et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J. Immunol. 2000, 164:436-442.
139. Rossowska J., Anger N., Kicielinska J., Pajtasz-Piasecka E., Bielawska-Pohl A., Wojas-Turek J., et al. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response. Immunobiology 2015, 220:389-398.
140. Salgado R., Junius S., Benoy I., Van Dam P., Vermeulen P., Van Marck E., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int. J. Cancer 2003, 103:642-646.
141. Frassanito M.A., Cusmai A., Iodice G., Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001, 97:483-489.
142. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 2000, 1:515-520.
143. Kusmartsev S., Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 2006, 55:237-245.
144. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
145. Bronte V., Chappell D.B., Apolloni E., Cabrelle A., Wang M., Hwu P., et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 1999, 162:5728-5737.
146. Shevach E.M. Suppressor T cells: rebirth, function and homeostasis. Curr. Biol. 2000, 10:R572-R575.
147. Peng L., Kjaergaard J., Plautz G.E., Awad M., Drazba J.A., Shu S., et al. Tumor-induced l-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J. Immunol. 2002, 169:4811-4821.
148. Shafer-Weaver K.A., Anderson M.J., Stagliano K., Malyguine A., Greenberg N.M., Hurwitz A.A., Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J. Immunol. 2009, 183:4848-4852.
149. Algarra I., Cabrera T., Garrido F. The HLA crossroad in tumor immunology. Hum. Immunol. 2000, 61:65-73.
150. Algarra I., Garcia-Lora A., Cabrera T., Ruiz-Cabello F., Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol. Immunother. 2004, 53:904-910.
151. Porgador A., Mandelboim O., Restifo N.P., Strominger J.L. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13140-13145.
152. Kambayashi T., Michaelsson J., Fahlen L., Chambers B.J., Sentman C.L., Karre K., et al. Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro. Eur. J. Immunol. 2001, 31:869-875.
153. Smyth M.J., Thia K.Y., Cretney E., Kelly J.M., Snook M.B., Forbes C.A., et al. Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol. 1999, 162:6658-6662.
154. Maeurer M.J., Gollin S.M., Martin D., Swaney W., Bryant J., Castelli C., et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 1996, 98:1633-1641.
155. Johnsen A.K., France J., Nagy N., Askew D., Abdul-Karim F.W., Gerson S.L., et al. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int. J. Cancer 2001, 91:366-372.
156. Zhou F., Chen J., Zhao K.N. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. J. Gen. Virol. 2013, 94:2504-2514.
157. Eljaafari A., Van Snick J., Voisin A., Cormont F., Farre A., Bienvenu J., et al. Alloreaction increases or restores CD40, CD54, and/or HLA molecule expression in acute myelogenous leukemia blasts, through secretion of inflammatory cytokines: dominant role for TNFbeta, in concert with IFNgamma. Leukemia 2006, 20:1992-2001.
158. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellstrom I., et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J. Exp. Med. 1994, 179:523-532.
159. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P., et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 2001, 194:481-489.
160. Wang X.Y., Zuo D., Sarkar D., Fisher P.B. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin. Pharmacother. 2011, 12:2695-2706.
161. Dias J.D., Hemminki O., Diaconu I., Hirvinen M., Bonetti A., Guse K., et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 2012, 19:988-998.
162. Fallarino F., Fields P.E., Gajewski T.F. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 1998, 188:205-210.
163. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
164. Tamura H., Ogata K., Dong H., Chen L. Immunology of B7-H1 and its roles in human diseases. Int. J. Hematol. 2003, 78:321-328.
165. Latchman Y.E., Liang S.C., Wu Y., Chernova T., Sobel R.A., Klemm M., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10691-10696.
166. Blank C., Gajewski T.F., Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 2005, 54:307-314.
167. Dorfman D.M., Shahsafaei A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 2011, 35:76-83.
168. Pallasch C.P., Ulbrich S., Brinker R., Hallek M., Uger R.A., Wendtner C.M. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk. Res. 2009, 33:460-464.
169. Wong K.K., Khatri I., Shaha S., Spaner D.E., Gorczynski R.M. The role of CD200 in immunity to B cell lymphoma. J. Leukoc. Biol. 2010, 88:361-372.
170. Enose-Akahata Y., Matsuura E., Oh U., Jacobson S. High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease. PLoS Pathog. 2009, 5:e1000682.
171. Mittal R., Chen C.W., Lyons J.D., Margoles L.M., Liang Z., Coopersmith C.M., et al. Murine lung cancer induces generalized T-cell exhaustion. J. Surg. Res. 2015, 195:541-549.
172. Zhang Y., Ertl H.C. The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion. J. Immunol. 2014, 193:1836-1846.
173. Zhou Q., Munger M.E., Veenstra R.G., Weigel B.J., Hirashima M., Munn D.H., et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011, 117:4501-4510.
174. Ngiow S.F., von Scheidt B., Akiba H., Yagita H., Teng M.W., Smyth M.J. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011, 71:3540-3551.
175. Nagahara K., Arikawa T., Oomizu S., Kontani K., Nobumoto A., Tateno H., et al. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 2008, 181:7660-7669.
176. Anderson A.C., Anderson D.E., Bregoli L., Hastings W.D., Kassam N., Lei C., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
177. Cai G., Freeman G.J. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol. Rev. 2009, 229:244-258.
178. Murphy K.M., Nelson C.A., Sedy J.R. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 2006, 6:671-681.
179. Truong W., Hancock W.W., Plester J.C., Merani S., Rayner D.C., Thangavelu G., et al. BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J. Leukoc. Biol. 2009, 86:41-51.
180. Derre L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. 2010, 120:157-167.
181. Albring J.C., Sandau M.M., Rapaport A.S., Edelson B.T., Satpathy A., Mashayekhi M., et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J. Exp. Med. 2010, 207:2551-2559.
182. Camisaschi C., Casati C., Rini F., Perego M., De Filippo A., Triebel F., et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J. Immunol. 2010, 184:6545-6551.
183. Matsuzaki J., Gnjatic S., Mhawech-Fauceglia P., Beck A., Miller A., Tsuji T., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7875-7880.
184. Henson S.M., Akbar A.N. KLRG1 - more than a marker for T cell senescence. Age (Dordr.) 2009, 31:285-291.
185. Bengsch B., Seigel B., Ruhl M., Timm J., Kuntz M., Blum H.E., et al. Coexpression of PD-1,2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 2010, 6:e1000947.
186. Hellstrom K.E., Chen L., Hellstrom I. Costimulation of T-cell-mediated tumor immunity. Cancer Chemother. Pharmacol. 1996, 38(Suppl.):S40-S41.
187. Townsend S.E., Allison J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993, 259:368-370.
188. Kundig T.M., Bachmann M.F., DiPaolo C., Simard J.J., Battegay M., Lother H., et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268:1343-1347.
189. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:2233-2238.
190. Chen W., Masterman K.A., Basta S., Haeryfar S.M., Dimopoulos N., Knowles B., et al. Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon. Eur. J. Immunol. 2004, 34:194-199.
191. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001, 411:1058-1064.
192. Staveley-O'Carroll K., Sotomayor E., Montgomery J., Borrello I., Hwang L., Fein S., et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1178-1183.
193. Ochsenbein A.F. Immunological ignorance of solid tumors. Springer Semin. Immunopathol. 2005, 27:19-35.
194. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
195. Robert C., Thomas L., Bondarenko I., O'Day S., DJ M., Garbe C.ET-AL> Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
196. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:2018-2028.
197. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2015, 18:2004-2012.
198. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., et al. Cancer immunology, mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
199. Caccamo N., Meraviglia S., Cicero G., Gulotta G., Moschella F., Cordova A., et al. Aminobisphosphonates as new weapons for gammadelta T cell-based immunotherapy of cancer. Curr. Med. Chem. 2008, 15:1147-1153.
200. Chiplunkar S., Dhar S., Wesch D., Kabelitz D. gammadelta T cells in cancer immunotherapy: current status and future prospects. Immunotherapy 2009, 1:663-678.
201. Roelofs A.J., Jauhiainen M., Monkkonen H., Rogers M.J., Monkkonen J., Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 2009, 144:245-250.
202. Castella B., Riganti C., Fiore F., Pantaleoni F., Canepari M.E., Peola S., et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vgamma9Vdelta2 T cells, alphabeta CD8+ T cells, regulatory T cells, and dendritic cells. J. Immunol. 2011, 187:1578-1590.
203. Nicol A.J., Tokuyama H., Mattarollo S.R., Hagi T., Suzuki K., Yokokawa K., et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br. J. Cancer 2011, 105:778-786.
204. Haribhai D., Lin W., Edwards B., Ziegelbauer J., Salzman N.H., Carlson M.R., et al. A central role for induced regulatory T cells in tolerance induction in experimental colitis. J. Immunol. 2009, 182:3461-3468.
205. Haribhai D., Lin W., Relland L.M., Truong N., Williams C.B., Chatila T.A. Regulatory T cells dynamically control the primary immune response to foreign antigen. J. Immunol. 2007, 178:2961-2972.
206. Roychoudhuri R., Eil R.L., Restifo N.P. The interplay of effector and regulatory T cells in cancer. Curr. Opin. Immunol. 2015, 33C:101-111.
207. Sakaguchi S. Immunologic tolerance maintained by regulatory T cells: implications for autoimmunity, tumor immunity and transplantation tolerance. Vox Sang. 2002, 83(Suppl. 1):151-153.
208. Rudensky A.Y. Regulatory T cells and Foxp3. Immunol. Rev. 2011, 241:260-268.
209. Marie J.C., Letterio J.J., Gavin M., Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med. 2005, 201:1061-1067.
210. Relland L.M., Mishra M.K., Haribhai D., Edwards B., Ziegelbauer J., Williams C.B. Affinity-based selection of regulatory T cells occurs independent of agonist-mediated induction of Foxp3 expression. J. Immunol. 2009, 182:1341-1350.
211. Moo-Young T.A., Larson J.W., Belt B.A., Tan M.C., Hawkins W.G., Eberlein T.J., et al. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J. Immunother. 2009, 32:12-21.
212. Petrausch U., Jensen S.M., Twitty C., Poehlein C.H., Haley D.P., Walker E.B., et al. Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J. Immunol. 2009, 183:3682-3689.
213. Chen M.L., Pittet M.J., Gorelik L., Flavell R.A., Weissleder R., von Boehmer H., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:419-424.
214. Sasada T., Kimura M., Yoshida Y., Kanai M., Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003, 98:1089-1099.
215. Nishikawa H., Kato T., Tawara I., Takemitsu T., Saito K., Wang L., et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9253-9257.
216. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
217. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006, 66:5716-5722.
218. Sun J., Han Z.B., Liao W., Yang S.G., Yang Z., Yu J., et al. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4+CD25+ Forkhead Boxp3 (FOXP3)+ regulatory T cells and balancing anti- and pro-inflammatory factors. Cell. Physiol. Biochem. 2011, 27:587-596.
219. Wang Y., Wang W., Wang L., Wang X., Xia J. Regulatory mechanisms of interleukin 8 production induced by tumor necrosis factor-alpha in human hepatocellular carcinoma cells. J. Cell. Mol. Med. 2012, 16:496-506.
220. Beyer M., Schultze J.L. Regulatory T cells: major players in the tumor microenvironment. Curr. Pharm. Des. 2009, 15:1879-1892.
221. Chaput N., Darrasse-Jeze G., Bergot A.S., Cordier C., Ngo-Abdalla S., Klatzmann D., et al. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J. Immunol. 2007, 179:4969-4978.
222. Addey C., White M., Dou L., Coe D., Dyson J., Chai J.G. Functional plasticity of antigen-specific regulatory T cells in context of tumor. J. Immunol. 2011, 186:4557-4564.
223. Chen Y.L., Fang J.H., Lai M.D., Shan Y.S. Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma. World J. Gastroenterol. 2008, 14:5797-5809.
224. Turk M.J., Guevara-Patino J.A., Rizzuto G.A., Engelhorn M.E., Sakaguchi S., Houghton A.N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 2004, 200:771-782.
225. Li Z., Li D., Tsun A., Li B. FOXP3 regulatory T cells and their functional regulation. Cell. Mol. Immunol. 2015.
226. Steitz J., Bruck J., Lenz J., Knop J., Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 2001, 61:8643-8646.
227. Furuichi Y., Tokuyama H., Ueha S., Kurachi M., Moriyasu F., Kakimi K. Depletion of CD25+CD4+ T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization. World J. Gastroenterol. 2005, 11:3772-3777.
228. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
229. Esparza E.M., Arch R.H. Signaling triggered by glucocorticoid-induced tumor necrosis factor receptor family-related gene: regulation at the interface between regulatory T cells and immune effector cells. Front. Biosci. 2006, 11:1448-1465.
230. Ko K., Yamazaki S., Nakamura K., Nishioka T., Hirota K., Yamaguchi T., et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 2005, 202:885-891.
231. Lehe C., Ghebeh H., Al-Sulaiman A., Al Qudaihi G., Al-Hussein K., Almohareb F., et al. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res. 2008, 68:6350-6359.
232. Rudolph M., Hebel K., Miyamura Y., Maverakis E., Brunner-Weinzierl M.C. Blockade of CTLA-4 decreases the generation of multifunctional memory CD4+ T cells in vivo. J. Immunol. 2011, 186:5580-5589.
233. Callahan M.K., Wolchok J.D., Allison J.P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 2010, 37:473-484.
234. Yamaguchi T., Hirota K., Nagahama K., Ohkawa K., Takahashi T., Nomura T., et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007, 27:145-159.
235. Ercolini A.M., Ladle B.H., Manning E.A., Pfannenstiel L.W., Armstrong T.D., Machiels J.P., et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 2005, 201:1591-1602.
236. Rasku M.A., Clem A.L., Telang S., Taft B., Gettings K., Gragg H., et al. Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 2008, 6:12.
237. Morse M.A., Hobeika A.C., Osada T., Serra D., Niedzwiecki D., Lyerly H.K., et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008, 112:610-618.
238. Mahnke K., Schonfeld K., Fondel S., Ring S., Karakhanova S., Wiedemeyer K., et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 2007, 120:2723-2733.
239. Barnett B., Kryczek I., Cheng P., Zou W., Curiel T.J. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am. J. Reprod. Immunol. 2005, 54:369-377.
240. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115:3623-3633.
241. Powell D.J., Felipe-Silva A., Merino M.J., Ahmadzadeh M., Allen T., Levy C., et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 2007, 179:4919-4928.
242. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
243. Khan S., Burt D.J., Ralph C., Thistlethwaite F.C., Hawkins R.E., Elkord E. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin. Immunol. 2011, 138:85-96.
244. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002, 16:311-323.
245. Shevach E.M., Stephens G.L. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity?. Nat. Rev. Immunol. 2006, 6:613-618.
246. Stephens G.L., McHugh R.S., Whitters M.J., Young D.A., Luxenberg D., Carreno B.M., et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 2004, 173:5008-5020.
247. Takeuchi A., Eto M., Yamada H., Tatsugami K., Naito S., Yoshikai Y. A reduction of recipient regulatory T cells by cyclophosphamide contributes to an anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation in mice. Int. J. Cancer 2012, 130:365-376.
248. Young K.J., DuTemple B., Phillips M.J., Zhang L. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J. Immunol. 2003, 171:134-141.
249. Zhang Z.X., Yang L., Young K.J., DuTemple B., Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat. Med. 2000, 6:782-789.
250. Fischer K., Voelkl S., Heymann J., Przybylski G.K., Mondal K., Laumer M., et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood 2005, 105:2828-2835.
251. Burnet F.M. Biology and medicine. Med. J. Aust. 1957, 44:406-410.
252. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
253. Grange M., Buferne M., Verdeil G., Leserman L., Schmitt-Verhulst A.M., Auphan-Anezin N. Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma. Cancer Res. 2012, 72:76-87.
254. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97:192-197.
255. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
256. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
257. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
258. Dunn G.P., Bruce A.T., Sheehan K.C., Shankaran V., Uppaluri R., Bui J.D., et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 2005, 6:722-729.
259. Shanker A., Verdeil G., Buferne M., Inderberg-Suso E.M., Puthier D., Joly F., et al. CD8T cell help for innate antitumor immunity. J. Immunol. 2007, 179:6651-6662.
260. Sadelain M., Brentjens R., Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 2009, 21:215-223.
261. Zhao Y., Wang Q.J., Yang S., Kochenderfer J.N., Zheng Z., Zhong X., et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 2009, 183:5563-5574.
262. Parker L.L., Do M.T., Westwood J.A., Wunderlich J.R., Dudley M.E., Rosenberg S.A., et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum. Gene Ther. 2000, 11:2377-2387.
263. Wang X., Riviere I. Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther. 2015, 22:85-94.
264. Cheadle E.J., Gilham D.E., Hawkins R.E. The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br. J. Haematol. 2008, 142:65-68.
265. Lamers C.H., Sleijfer S., Vulto A.G., Kruit W.H., Kliffen M., Debets R., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 2006, 24:e20-e22.
266. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
267. Pule M.A., Savoldo B., Myers G.D., Rossig C., Russell H.V., Dotti G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 2008, 14:1264-1270.
268. Bridgeman J.S., Hawkins R.E., Bagley S., Blaylock M., Holland M., Gilham D.E. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 2010, 184:6938-6949.
269. Bridgeman J.S., Hawkins R.E., Hombach A.A., Abken H., Gilham D.E. Building better chimeric antigen receptors for adoptive T cell therapy. Curr. Gene Ther. 2010, 10:77-90.
270. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
271. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3:95ra73.
272. Liu L., Sun M., Wang Z. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors. Cancer Lett. 2011, 316:1-5.
273. Kerkar S.P., Sanchez-Perez L., Yang S., Borman Z.A., Muranski P., Ji Y., et al. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J. Immunother. 2011, 34:343-352.
274. Vatakis D.N., Koya R.C., Nixon C.C., Wei L., Kim S.G., Avancena P., et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 274:1408-1416.
275. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116:1035-1044.
276. Liu S., Riley J., Rosenberg S., Parkhurst M. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 2006, 29:284-293.
277. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 2009, 9:480-490.
278. Stephan M.T., Moon J.J., Um S.H., Bershteyn A., Irvine D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 2010, 16:1035-1041.
279. Pardoll D.M. Building the bionic T cell. Nat. Med. 2007, 13:1411-1413.
280. Stephan M.T., Ponomarev V., Brentjens R.J., Chang A.H., Dobrenkov K.V., Heller G., et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 2007, 13:1440-1449.
281. Cioffi M., Dorado J., Baeuerle P.A., Heeschen C. EpCAM/CD3-bispecific T cell engaging antibody M110 eliminates primary human pancreatic cancer stem cells. Clin. Cancer Res. 2011, 18:465-474.
282. Seidel U.J., Oliveira C.C., Lampen M.H., van Hall T. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens. Cancer Immunol. Immunother. 2011, 61:119-125.
283. Winter H., Hu H.-M., Urba W.J., Fox B.A. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J. Immunol. 1999, 163:4462-4472.
284. Cretney E., Shanker A., Yagita H., Smyth M.J., Sayers T.J. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. 2006, 84:87-98.
285. Seki N., Hayakawa Y., Brooks A.D., Wine J., Wiltrout R.H., Yagita H., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003, 63:207-213.
286. Shanker A., Buferne M., Schmitt-Verhulst A.M. Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity. Immunology 2010, 129:41-54.
287. Shanker A., Brooks A.D., Jacobsen K.M., Wine J.W., Wiltrout R.H., Yagita H., et al. Antigen presented by tumors in vivo determines the nature of CD8(+) T-cell cytotoxicity. Cancer Res. 2009, 69:6615-6623.
288. Shanker A., Brooks A.D., Tristan C.A., Wine J.W., Elliott P.J., Yagita H., et al. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J. Natl. Cancer Inst. 2008, 100:649-662.
289. Shanker A., Sayers T. Sensitizing tumor cells to immune-mediated cytotoxicity. Immune-Mediated Diseases: From Theory to Therapy 2007, 163-171. Springer, Moscow. M.R. Shurin, Y.S. Smolkin (Eds.).
290. Hallett W.H.D., Ames E., Motarjemi M., Barao I., Shanker A., Tamang D.L., et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 2008, 180:163-170.
291. Malhotra A., Shanker A. NK cells: immune cross-talk and therapeutic implications. Immunotherapy 2011, 3:1143-1166.
292. Banerjee D., Hernandez S.L., Garcia A., Kangsamaksin T., Sbiroli E., Andrews J., et al. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res. 2015, 75:1592-1602.
293. Prokopi M., Kousparou C.A., Epenetos A.A. The secret role of microRNAs in cancer stem cell development and potential therapy: a notch-pathway approach. Front. Oncol. 2014, 4:389.
294. Salvadori S., Zier K. Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2. J. Immunol. 1996, 156:2927-2932.
295. Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T., et al. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J. Immunol. 1995, 155:1382-1392.